Overview

A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults

Status:
Active, not recruiting
Trial end date:
2023-02-10
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AZD7442 in Healthy Chinese Adults. vs. placebo
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca